Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study

BACKGROUND: Vaniprevir is a potent macrocyclic hepatitis C virus (HCV) nonstructural protein 3/4A protease inhibitor. This phase III study evaluated the safety and efficacy of vaniprevir in combination with peginterferon alfa-2b and ribavirin (PR) for 24 weeks compared with PR alone for 48 weeks in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Gastroenterol
Main Authors: Hayashi, Norio, Nakamuta, Makoto, Takehara, Tetsuo, Kumada, Hiromitsu, Takase, Akiko, Howe, Anita Yee Mei, Ludmerer, Steven W., Mobashery, Niloufar
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Japan 2015
Assuntos:
Original Article—Liver, Pancreas, and Biliary Tract
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4805724/
https://ncbi.nlm.nih.gov/pubmed/26403160
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00535-015-1120-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados